Lexicon Pharmaceuticals LXRX Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Lexicon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The official record: Lexicon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Lexicon Pharmaceuticals's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Lexicon Pharmaceuticals's total equity?
- Lexicon Pharmaceuticals (LXRX) reported total equity of $202.86M in Q1 2026.
- How has Lexicon Pharmaceuticals's total equity changed year-over-year?
- Lexicon Pharmaceuticals's total equity increased by 64.9% year-over-year, from $123.03M to $202.86M.
- What is the long-term trend for Lexicon Pharmaceuticals's total equity?
- Over 5 years (2020 to 2025), Lexicon Pharmaceuticals's total equity has grown at a -7.2% compound annual growth rate (CAGR), from $156.37M to $107.54M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.